SCHEMBL352919

SCHEMBL352919

CN(Cc1csc(NC(=O)NCc2cccc(F)c2)n1)C(=O)c1c(Cl)cnn1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 13/20 0.49
ROCK1 Q13464 13/20 0.49
EPHX2 P34913 1/20 0.42
MAPK1 P28482 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
AKT1 P31749 2/20 0.38
SGK1 O00141 1/20 0.38
GSK3B P49841 1/20 0.38
LIMK1 P53667 1/20 0.38
TNK2 Q07912 1/20 0.38
DMPK Q09013 1/20 0.38
MYLK Q15746 1/20 0.38
CDC42BPA Q5VT25 1/20 0.38
NAMPT P43490 1/20 0.38
CIT O14578 1/20 0.38
PRKCB P05771 1/20 0.38
PRKCA P17252 1/20 0.38
PRKACA P17612 1/20 0.38
PRKACB P22694 1/20 0.38
AKT2 P31751 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354243 0.90 ROCK2 (0.50) ROCK2ROCK1EPHX2MAPK1ATG4B
SCHEMBL19118736 0.88 ROCK1 (0.48) ROCK2ROCK1EPHX2MAPK1ATG4B
SCHEMBL353801 0.86 ROCK2 (0.50) ROCK2ROCK1EPHX2MAPK1ATG4B
SCHEMBL351670 0.84 ROCK1 (0.48) ROCK2ROCK1MAPK1ATG4BAKT1
SCHEMBL19119187 0.84 ROCK1 (0.48) ROCK2ROCK1EPHX2MAPK1ATG4B
SCHEMBL353244 0.84 ROCK2 (0.49) ROCK2ROCK1EPHX2MAPK1ATG4B
SCHEMBL352722 0.84 ROCK2 (0.47) ROCK2ROCK1MAPK1ATG4BAKT1
SCHEMBL352768 0.84 ATG4B (0.49) ROCK2ROCK1ATG4BNAMPT
SCHEMBL352918 0.83 ROCK2 (0.49) ROCK2ROCK1EPHX2MAPK1ATG4B
SCHEMBL353920 0.82 ROCK2 (0.51) ROCK2ROCK1EPHX2ATG4BAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA ROCK2 4626/4885ROCK1 4747/4885EPHX2 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.